PP
ARCT icon

Paloma Partners’s Arcturus Therapeutics ARCT Stock Holding History

Paloma Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-32
Closed -$4K – 676
2013
Q4 		$4K Buy
+32
New +$4.02K ﹤0.01% 979

Other funds holding ARCT

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
TMC
Trellus Management Company Delray Beach, Florida $72.8M AUM 4.5% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
BAAM
Baker Avenue Asset Management San Francisco, California $5.28B AUM 39.19% 1-Year Est. Return

Paloma Partners's ARCT Position: Q1 2014 in Review

Paloma Partners sold out of Arcturus Therapeutics (ARCT) in Q1 2014, closing a stake of 32 shares — an estimated $4K sold.

Paloma Partners first reported a position in ARCT in Q4 2013 and held it in 1 quarter. The position peaked at $4K in Q4 2013. 24 funds tracked by Wall St. Rank hold ARCT as of Q1 2014.

  • Paloma Partners reported no remaining Arcturus Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Paloma Partners sold 32 Arcturus Therapeutics shares in Q1 2014, an estimated $4K.
  • Paloma Partners first reported a position in Arcturus Therapeutics in Q4 2013 and held it in 1 quarter.
  • Paloma Partners's Arcturus Therapeutics position peaked at $4K in Q4 2013.
  • 24 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2014.

Based on Paloma Partners's 13F filing for Q1 2014, filed 15 May 2014.